Clinical trials: Hepatocellular Carcinoma Resectable
Hepatocellular Carcinoma
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab adjuvant therapy alone in patients with…
- Trial name
- CAPT (NCT04930315)
- Testing
- Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC)
A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
This is an early-phase study testing a new combination treatment for cancer. participants will receive a type of radiation therapy called MRI-guided or CT-guided radiotherapy, depending on which imaging method is safe for them.
- Trial name
- PRISM (NCT06994299)
- Testing
- Radiation Therapy, Tremelimumab, Durvalumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Patients suffering from advanced stage hepatocellular carcinoma (HCC) who have shown disease progression during lenvatinib-based first line treatment, will be enrolled in this trial.
- Trial name
- NCT04511455
- Testing
- Cabozantinib
- Where
- 10 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
The purpose of this study is to compare the survival outcomes between hepatic resection and transarterial lipiodol chemoembolization (TACE) used as the initial treatment in patients with Resectable Hepatocellular Carcinoma Beyond…
- Trial name
- NCT02138981
- Testing
- Chemoembolization and Response-Dependent Resection, Immediate Resection
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC.
- Trial name
- NCT05908786
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 14 sites in United States, Austria and 4 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC).
- Trial name
- DARTS (NCT07027436)
- Testing
- Chemotherapy/Radiation
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Hamilton Health Sciences Corporation
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma Non-resectable
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT06397222
- Testing
- Sin-Bev-SIRT
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Resectable Hepatocellular Carcinoma
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ASPIRE (NCT07018947)
- Testing
- Atezolizumab and Bevacizumab
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Hepatocellular Carcinoma Resectable
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition.
- Trial name
- NCT06294808
- Where
- 2 sites in Singapore
- Volunteers
- 1,043 people
- Sponsor
- National Cancer Centre, Singapore
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Resectable
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
- Trial name
- NCT05766605
- Testing
- Oxaliplatin, Doxorubicin, Lobaplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhujiang Hospital
Hepatocellular Carcinoma
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion.
- Trial name
- NCT03908840
- Testing
- TBI 302
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Evolve Biologics
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
It is an open,randomized,controlled study, and the purpose of this study is to observe and evaluate the efficacy and safety of Apatinib combined with Capecitabine in the treatment of patients with advanced hepatocellular…
- Trial name
- NCT03114085
- Testing
- Capecitabine, Apatinib
- Volunteers
- 170 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01239355
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-Resectable
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
This study is to assess the efficacy and the safety of hepatic arterial infusion of cisplatin and 5-fluorouracil (HAIC) in advanced HCC patients stratified by biomarker expression predicting therapeutic response.
- Trial name
- SHINE (NCT02967887)
- Testing
- cisplatin and 5-fluorouracil
- Where
- 12 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- CbsBioscience
Hepatocellular Carcinoma
Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion
The purpose of this study is to compare the effects of different multimodality therapy strategies (initial hepatectomy followed by transcatheter hepatic arterial chemoembolization and/or local regional treatments compare with…
- Trial name
- MDTforHCC (NCT00501813)
- Testing
- Hepatectomy, TACE combined with local regional therapies without hepatectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of…
- Trial name
- NCT05530785
- Testing
- radiotherapy combined with sintilimab and bevacizumab biosimilar
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yongchang Zhang
Hepatocellular Carcinoma Resectable
Hypermethylation of VTRNA2-1 Promoter in HCC Outcome
The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled.
- Trial name
- NCT04177316
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- Chang Gung Memorial Hospital